mTOR activity can also be stimulated, independently of the PI3K pathway, by CDK4 and PIM kinases [13–16], both of which have been identified as potential mechanisms of resistance to PI3K inhibitors in breast cancer [6, 15]. Here, PIK3CA is linked to breast cancer.